secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monopar Therapeutics (MNPR)
CIK:        0001645469
Form:       8-K
Filed at:   2024-06-11T23:59:59+00:00
Accession:  0001437749-24-019881
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monopar expands NorthStar collaboration; secures Ac-225 supply & full MNPR-101 IP ownership
--------------------------------------------------------------------------------

- Long-term master supply agreement for actinium-225 from NorthStar for Monopar's development and commercial programs.
- Monopar acquires full ownership of MNPR-101 radiopharmaceutical platform and related jointly developed IP from NorthStar.
- Both companies share ownership of filed patent application on PCTA linker with Ac-225, showing superior binding vs. DOTA.
- NorthStar expected to be first commercial-scale producer of non-carrier added Ac-225 using electron accelerator technology.
- No financial terms disclosed; collaboration builds on NorthStar's Ac-225 manufacturing and Monopar's preclinical results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924019881/0001437749-24-019881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645469/000143774924019881/mnpr20240610_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-019881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer